Technologies

The turnover of the private company UAB Sicor Biotech / TEVA - leader of Lithuanian biopharmacy - increased by 49% during the first half of this year and reached 52.67 million litas.

"We are working hard to increase export and quickly break into new markets. That’s why we are taking more orders for medicine manufacture in Lithuania. Great results in the first half of the year were mainly influenced by the sales of TevaGrastim - a medicine for oncological patients, which was registered in the EU last year," says Assoc. Prof. Dr. Vladas Algirdas Bumelis, UAB Sicor Biotech / TEVA Director General.

According to the Director General, the export of products with high added value manufactured in the company forms 70% of sales. "Being a part of the TEVA group we have exceptional opportunities to expand our export markets. We can also cooperate with scientists from other biopharmacy companies within the TEVA group and work together to create new advanced biotechnological medicine," says Prof. Bumelis, leader of the Lithuanian scientist team.

"Sicor Biotech products are sold in more than 30 countries worldwide. By our endeavours we are trying to contribute to the growth of the Lithuanian economy. We are planning to double our exports within the next few years," adds the head of Sicor Biotech.

UAB Sicor Biotech is a biotechnological pharmacy company and has been working in the field of advanced biotechnology for more than 20 years. In 2004 the company joined the group of the world’s largest genetic medicine producer - Teva. UAB Sicor Biotech is the only company in Central and Eastern Europe that produces modern recombinant biopharmaceutical medicine. The company conducts research on products in the following fields: biochemistry, molecular biology, modern genetic engineering, biosynthesis and biopharmacy.

UAB Sicor Biotech four times has been recognized as Lithuania’s top exporter of the year and the company’s medicine Realdiron Set and Tevagrastim received the Product of the Year award. The head of the company Prof. Bumelis is a winner of the Lithuanian Science Award and the National Award of Advancement, as well as the Swedish Innovation Award, the Lithuanian Science and Business Partnership Award Gyvybės Medis (an award for important achievements in natural and medical sciences) and many more honours. The Lithuanian Confederation of Industrialists acknowledged the company’s merits to the country’s economy and awarded three Sicor Biotech leaders with Profesijos Riteris (a very great honour in Lithuania) badges and certificates.